retatrutide triple hormone receptor agonist obesity mechanism of action A review an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology retatrutide triple hormone receptor agonist

Design your exit ramp from day one

A US Food and Drug Administration advisory committee is scheduled to meet in July 2026 to consider whether pharmacies should be permitted to compound and sell seven unapproved peptides, with BPC-157 among them

GLP-1 medications are intriguing from a cancer research perspective because they werent designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so were eager to study them in this context, McDonald said

Ongoing Phase 3 programs extend these findings by examining long-term metabolic stability and cardiovascular implications of glucagon-inclusive therapies

Many peptides act as signalling molecules, telling cells what to do